Targeted agent use in cancer patients at the end of life

Journal of Pain and Symptom Management

Volumn 46, Issue 1, 2013, Pages 1-8

  Hui, David ^a   Karuturi, Meghan Sri ^a   Tanco, Kimberson Cochien ^a   Kwon, Jung Hye ^a,b   Kim, Sun Hyun ^c   Zhang, Tao ^a   Kang, Jung Hun ^a,d   Chisholm, Gary ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Hallym University   (South Korea)

^c Catholic Kwandong University   (South Korea)

^d Gyeongsang National University School of Medicine   (South Korea)

Author keywords

Antineoplastic agents; end of life; palliative care; quality of care; supportive care; targeted agents

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; GEMTUZUMAB; LENALIDOMIDE; METHOTREXATE; PACLITAXEL; PEMETREXED; RITUXIMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRAMETINIB; TRASTUZUMAB;

ACUTE LEUKEMIA; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CHRONIC LEUKEMIA; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSIS; DISEASE ASSOCIATION; DRUG TARGETING; FEMALE; GASTROINTESTINAL CARCINOMA; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; SEX RATIO; TERMINAL CARE; UROGENITAL TRACT CANCER;

ANTINEOPLASTIC AGENTS; END OF LIFE; PALLIATIVE CARE; QUALITY OF CARE; SUPPORTIVE CARE; TARGETED AGENTS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; QUALITY OF LIFE; TERMINAL CARE;

EID: 84877582835     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2012.07.007     Document Type: Article

References (32)

1. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
2. J.S. de Bono, and A. Ashworth Translating cancer research into targeted therapeutics Nature 467 2010 543 549
3. N. Saijo Progress in cancer chemotherapy with special stress on molecular-targeted therapy Jpn J Clin Oncol 40 2010 855 862
4. D. Hui, A. Con, G. Christie, and P.H. Hawley Goals of care and end-of-life decision making for hospitalized patients at a Canadian tertiary care cancer center J Pain Symptom Manage 38 2009 871 881
5. S. Setoguchi, C.C. Earle, and R. Glynn Comparison of prospective and retrospective indicators of the quality of end-of-life cancer care J Clin Oncol 26 2008 5671 5678
6. C.C. Earle, M.B. Landrum, and J.M. Souza Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 26 2008 3860 3866
7. C.C. Earle, E.R. Park, and B. Lai Identifying potential indicators of the quality of end-of-life cancer care from administrative data J Clin Oncol 21 2003 1133 1138 (Pubitemid 46594144)
8. S.T. Tang, S.C. Wu, and Y.N. Hung Determinants of aggressive end-of-life care for Taiwanese cancer decedents, 2001 to 2006 J Clin Oncol 27 2009 4613 4618
9. A.S. Wong, C. Teo, and S.W. Lim Targeted therapy at the end of life for patients with lung cancer J Palliat Med 13 2010 945 948
10. D. Hui, A. Elsayem, and Z. Li Antineoplastic therapy use in patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center: a simultaneous care model Cancer 116 2010 2036 2043
11. Hui D, Kim SH, Kwon JH, et al. Access to palliative care before death among patients treated at a comprehensive cancer center. Oncologist. In press.
12. C.C. Earle, B.A. Neville, and M.B. Landrum Trends in the aggressiveness of cancer care near the end of life J Clin Oncol 22 2004 315 321 (Pubitemid 41095097)
13. S.E. Harrington, and T.J. Smith The role of chemotherapy at the end of life: "when is enough, enough?" JAMA 299 2008 2667 2678 (Pubitemid 351831596)
14. National Cancer Institute. Targeted therapy. IN: National Cancer Institute dictionary of cancer terms. 2012. Available from http://www.cancer. gov/dictionary?cdrid=270742. Accessed March 5, 2012.
15. C. Guevremont, A. Alasker, and P.I. Karakiewicz Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma Curr Opin Support Palliat Care 3 2009 170 179
16. B. Burtness, M. Anadkat, and S. Basti NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer J Natl Compr Canc Netw 7 Suppl 1 2009 S5 21 Quiz S22-24
17. A.F. Galimont-Collen, L.E. Vos, A.P. Lavrijsen, J. Ouwerkerk, and H. Gelderblom Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors Eur J Cancer 43 2007 845 851 (Pubitemid 46366684)
18. I.N. Daher, and E.T. Yeh Vascular complications of selected cancer therapies Nat Clin Pract Cardiovasc Med 5 2008 797 805
19. S.M. Gressett, and S.R. Shah Intricacies of bevacizumab-induced toxicities and their management Ann Pharmacother 43 2009 490 501
20. M. Zangari, L.M. Fink, and F. Elice Thrombotic events in patients with cancer receiving antiangiogenesis agents J Clin Oncol 27 2009 4865 4873
21. S.A. Soefje, A. Karnad, and A.J. Brenner Common toxicities of mammalian target of rapamycin inhibitors Target Oncol 6 2011 125 129
22. F. Torino, S.M. Corsello, R. Longo, A. Barnabei, and G. Gasparini Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy Nat Rev Clin Oncol 6 2009 219 228
23. C.B. Boers-Doets, J.B. Epstein, and J.E. Raber-Durlacher Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review Oncologist 17 2012 135 144
24. E. Amir, B. Seruga, and J. Martinez-Lopez Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs J Clin Oncol 29 2011 2543 2549
25. E.A. Grunfeld, E.J. Maher, and S. Browne Advanced breast cancer patients' perceptions of decision making for palliative chemotherapy J Clin Oncol 24 2006 1090 1098 (Pubitemid 46638806)
26. E.A. Grunfeld, A.J. Ramirez, and E.J. Maher Chemotherapy for advanced breast cancer: what influences oncologists' decision-making? Br J Cancer 84 2001 1172 1178 (Pubitemid 32511333)
27. N.A. Christakis, and E.B. Lamont Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study BMJ 320 2000 469 472 (Pubitemid 30173113)
28. D. Hui, K. Kilgore, and L. Nguyen The accuracy of probabilistic versus temporal clinician prediction of survival for patients with advanced cancer: a preliminary report Oncologist 16 2011 1642 1648
29. M. Maltoni, A. Caraceni, and C. Brunelli Prognostic factors in advanced cancer patients: evidence-based clinical recommendations-A study by the Steering Committee of the European Association for Palliative Care J Clin Oncol 23 2005 6240 6248
30. E. Bruera, N. Russell, C. Sweeney, M. Fisch, and J.L. Palmer Place of death and its predictors for local patients registered at a comprehensive cancer center J Clin Oncol 20 2002 2127 2133 (Pubitemid 34408804)
31. D. Hui, A. Elsayem, and S. Palla Discharge outcomes and survival of patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center J Palliat Med 13 2010 49 57
32. W.W. Cheng, J. Willey, J.L. Palmer, T. Zhang, and E. Bruera Interval between palliative care referral and death among patients treated at a comprehensive cancer center J Palliat Med 8 2005 1025 1032 (Pubitemid 41579244)